Credit Carry Forward

In the context of the Ohio R&D tax credit, Credit Carry Forward refers to the statutory right of a taxpayer to apply unused portions of a nonrefundable credit against future tax liabilities for a period of seven years. This mechanism ensures that high-innovation firms can eventually capture the full economic value of their research investments even if their immediate tax obligations are lower than the credit generated.

The Ohio Research and Development (R&D) Investment Tax Credit represents a cornerstone of the state’s economic development strategy, designed to incentivize technological innovation and high-wage job creation within the borders of Ohio. To understand the mechanism of Credit Carry Forward, one must first examine the broader tax environment in which it operates, primarily the transition from the legacy Corporate Franchise Tax to the contemporary Commercial Activity Tax (CAT). For decades, Ohio utilized a net income or net worth-based franchise tax, but the enactment of House Bill 66 in 2005 initiated a fundamental shift toward the CAT, which is a privilege tax measured by taxable gross receipts. Within this transition, the R&D tax credit was preserved and “converted” to ensure that the state remained competitive in attracting research-intensive industries such as aerospace, biotechnology, and advanced manufacturing.

The statutory authority for the current iteration of the R&D credit is found in Section 5751.51 of the Ohio Revised Code (R.C.). This section explicitly establishes that the credit is nonrefundable, a classification that necessitates the carry forward provision. In the landscape of state taxation, nonrefundable credits serve as an offset to liability; they can reduce a taxpayer’s burden to zero, but any excess credit does not trigger a payment from the state treasury back to the taxpayer. Consequently, without a carry forward mechanism, a company that invests heavily in R&D but has low sales in a particular year would lose the benefit of its investment. The Ohio General Assembly addressed this by providing a seven-year window for taxpayers to utilize these excess amounts.

Statutory Definitions and the Alignment with Federal Standards

The foundational definition of the Ohio R&D tax credit is inextricably linked to federal tax law. Under R.C. 5751.51(A), the term “qualified research expenses” (QREs) is defined as having the same meaning as in Section 41 of the Internal Revenue Code (IRC). This alignment provides a degree of administrative simplicity, as it allows Ohio taxpayers to utilize the same “Four-Part Test” established by the Internal Revenue Service (IRS) to determine eligibility. This test requires that the research must be undertaken for the purpose of discovering information that is technological in nature, the application of which is intended to be useful in the development of a new or improved business component, and substantially all of the activities must constitute a process of experimentation.

However, the Ohio statute introduces a critical jurisdictional limitation that does not exist at the federal level. While the federal credit applies to research conducted anywhere within the United States, the Ohio credit is strictly restricted to QREs “incurred in this state by the taxpayer”. This geographical nexus is a frequent point of contention during audits, as taxpayers must affirmatively demonstrate that the wages, supplies, and contract research costs claimed were tied to activities physically performed within Ohio’s boundaries.

The Incremental Nature of the Credit

The Ohio R&D credit is not a flat credit on all research spending. Instead, it is an incremental credit designed to reward growth in research investment. The credit amount is calculated as seven percent (7%) of the excess of the current year’s Ohio QREs over the taxpayer’s average annual QREs for the three preceding years. The following table illustrates the core components of this calculation as prescribed by the Ohio Department of Taxation.

Component	Description	Legal Reference
Current Year QREs	All qualified wages, supplies, and 65% of contract research incurred in Ohio.	R.C. 5751.51(B)(1)(a)
Base Amount	The average of Ohio QREs from the three preceding calendar years.	R.C. 5751.51(B)(1)(b)
Excess QREs	The difference between current QREs and the Base Amount.	R.C. 5751.51(B)(1)
Credit Value	7% of the Excess QREs.	R.C. 5751.51(B)(1)

If a taxpayer has a history of research in Ohio that is less than three years, the average is calculated based on the available history. For a company new to the state, the base amount may be zero, effectively allowing the credit to apply to the entirety of the first year’s qualified expenses.

The Evolution of the Commercial Activity Tax (CAT) Landscape

The utility and application of Credit Carry Forwards are deeply influenced by the structural mechanics of the Commercial Activity Tax. The CAT is not an income tax; it is a tax on the privilege of doing business in Ohio, and it applies to most business entities, including C-corporations, S-corporations, partnerships, and limited liability companies (LLCs). The tax is generally calculated by applying a rate of 0.26% (0.0026) to Ohio taxable gross receipts (TGR) that exceed a specific exclusion threshold.

Recent legislative reforms under House Bill 33 have significantly altered the CAT landscape for 2024 and 2025, which in turn shifts the strategic importance of R&D credit carry forwards. For the past decade, the CAT included an Annual Minimum Tax (AMT) that ranged from $150 to $2,600 based on the prior year’s receipts. However, beginning January 1, 2024, the AMT was eliminated, and the exclusion threshold was dramatically increased.

Tax Year	Exclusion Threshold	Rate on Receipts Above Exclusion	AMT Status
Pre-2024	$1,000,000	0.26%	Active ($150 – $2,600)
2024	$3,000,000	0.26%	Eliminated
2025 and Beyond	$6,000,000	0.26%	Eliminated

These changes imply that many small to mid-sized businesses will no longer have any CAT liability. For these entities, any R&D credits generated will automatically become carry forward credits, as there is no tax liability to offset. This necessitates a long-term view of tax planning, as these credits will sit on the company’s books for up to seven years, awaiting a year in which Ohio TGR exceeds the $6,000,000 threshold.

Regulatory Guidance from the Ohio Department of Taxation

The Ohio Department of Taxation (ODT) provides administrative guidance through Ohio Administrative Code (O.A.C.) Rule 5703-29-22 and various information releases. These rules clarify the “Credit Schedule” (Form CAT CS) and the rigorous documentation standards expected during an audit. Unlike some other state credits, the R&D Investment Tax Credit does not require an application or pre-approval from the Ohio Department of Development. It is a self-claimed credit, which places the burden of proof entirely on the taxpayer.

The Order of Credit Application

One of the most critical aspects of ODT guidance pertains to the order in which credits must be claimed. R.C. 5751.98 dictates a specific hierarchy to ensure a uniform procedure for calculating tax due. This hierarchy is essential because a taxpayer may possess multiple different types of credits, some of which may have shorter carry forward periods than others.

The R&D Investment Tax Credit is positioned early in the sequence:

1. Nonrefundable Jobs Retention Credit (R.C. 5751.50(B))
2. Nonrefundable Credit for Qualified Research Expenses (R.C. 5751.51)
3. Nonrefundable Credit for R&D Loan Payments (R.C. 5751.52)
4. Nonrefundable Credit for Unused Net Operating Losses (R.C. 5751.53)
5. Various Refundable Credits.

Regulatory guidance specifies that when a taxpayer carries forward an unused credit to a later year, that carry forward must be used after any preceding credit in the list but prior to the same credit generated in the current year. This “First-In, First-Out” (FIFO) approach is a protection for the taxpayer, as it ensures that the credits closest to their seven-year expiration date are exhausted first.

Audit Sampling and Documentation

In recent years, the ODT has adopted an increasingly rigorous audit posture. House Bill 33 codified the Commissioner’s authority to audit a “sample” of a taxpayer’s QREs over a representative period. The commissioner is tasked with making a good-faith effort to reach an agreement on the sample, but the absence of such an agreement does not preclude the audit from proceeding.

The documentation required to survive such an audit is extensive. Taxpayers are advised to maintain records for at least four years after the return is filed. However, because the credit relies on a three-year historical average, the practical record-retention period is often closer to seven or eight years to justify the base amount used in the calculation. Key documents include time-tracking logs for research personnel, project design documents, and detailed invoices for supplies and contract research.

Mechanism of the Seven-Year Carry Forward

The seven-year carry forward period established in R.C. 5751.51(B)(2) is a “rolling” period. Each year that a credit is generated but not fully utilized, the “excess” amount enters its own seven-year lifecycle. If the credit is not used within that timeframe, it expires and is lost forever.

Interaction with the 2008 Conversion

The history of the carry forward mechanism includes a unique provision for companies that held R&D credits under the old Corporate Franchise Tax. R.C. 5751.51(B)(3) and R.C. 5733.351(B) allowed for these legacy credits to be applied against the CAT. However, the total number of years for which the credit could be carried forward—combining the years under the Franchise Tax and the CAT—was capped at seven. This transitional rule has mostly phased out by the current decade, but it highlights the state’s intent to maintain a strict seven-year temporal limit on these nonrefundable incentives.

Group Membership and Credit Survival

Special rules apply to taxpayers that are part of a “consolidated elected” or “combined” group. R.C. 5751.51(C) requires that each member of the group calculate its credit separately based on its own QREs. However, the group as a whole files a single return and applies the credits collectively against the group’s CAT liability.

A complex nuance exists regarding changes in group membership. A group can only claim an excess credit carried forward with respect to persons who were members of that group as of the last day of the tax period for which the return is filed. If a research-heavy subsidiary is sold, the carry forward credits it generated may effectively leave the group with that subsidiary, or they may be lost depending on the terms of the transaction and the ODT’s interpretation of “successor-in-interest” rules.

Research and Development Loan Payment Credit: A Parallel Incentive

It is essential to distinguish the R&D Investment Tax Credit (R.C. 5751.51) from the R&D Loan Payment Tax Credit (R.C. 5747.331 and 5751.52). While they share a focus on innovation, their mechanics and carry forward rules differ significantly.

The Loan Payment Credit is based on payments made on loans issued by the Director of Development for R&D projects. Under R.C. 5747.331 (for individuals/PTEs) and R.C. 5751.52 (for CAT), this credit is also nonrefundable. However, the carry forward provision for the individual income tax version of this credit is often more generous, allowing the credit to be carried forward “until fully used,” without the strict seven-year limit found in the CAT Investment Credit. For the CAT version, the credit follows the order of application in R.C. 5751.98 and is generally carried forward until utilized.

Comprehensive Detailed Example: The Lifecycle of a Carry Forward

To illustrate the mathematical and legal application of the carry forward, consider “Precision Aerospace Ohio,” a manufacturer that conducts all its R&D in Cincinnati.

Year 1: Baseline and Credit Generation (2022)

In 2022, Precision Aerospace invests $3,000,000 in qualified research. Its previous three years of Ohio QREs were $2,000,000 (2021), $2,000,000 (2020), and $2,000,000 (2019).

1. Calculate Base Amount: (2M + 2M + 2M) / 3 = $2,000,000.
2. Calculate Excess: $3,000,000 – $2,000,000 = $1,000,000.
3. Calculate Credit: $1,000,000 × 7% = $70,000.

In 2022, the company’s CAT liability is $40,000.

• Credit Applied: $40,000 (reducing CAT to zero).
• Carry Forward (Expiring 2029): $30,000.

Year 2: The High-Growth Year (2023)

In 2023, research spending remains at $3,000,000. The new 3-year average (2020-2022) is (2M + 2M + 3M) / 3 = $2,333,333.

1. Calculate Excess: $3,000,000 – $2,333,333 = $666,667.
2. Calculate Credit: $666,667 × 7% = $46,667.

In 2023, the company has a banner year with CAT liability of $150,000.

• Step 1: Apply Carry Forward. The company uses the $30,000 carry forward from 2022 first.
• Step 2: Apply Current Credit. The company uses the $46,667 generated in 2023.
• Total Credits Used: $76,667.
• Net CAT Paid: $150,000 – $76,667 = $73,333.
• Remaining Carry Forward: $0.

Year 3: The 2025 Threshold Shift (2025)

By 2025, the company has increased its research significantly to $5,000,000. The 3-year average (2022-2024) is now $3,666,667.

1. Calculate Credit: ($5M – $3.66M) × 7% = $93,333.

However, in 2025, the company’s Ohio sales are $5,500,000. Under the new law, the exclusion is $6,000,000.

• 2025 CAT Liability: $0.
• 2025 Credit Utilization: $0.
• Carry Forward (Expiring 2032): $93,333.

This illustrates the “ripple effect” of the 2025 legislative changes. Precision Aerospace is still innovating at a high level, but because of the increased exclusion, it is generating credits that will not be used until its sales exceed $6,000,000. The company must meticulously track this $93,333 on its CAT CS schedules through the year 2032.

Mathematical Formulation of Credit Carry Forward

For financial reporting and tax compliance, the carry forward (CF) for any given year (t) can be expressed through the following notation:

CF_t = Σ (GeneratedCredit_i – AppliedCredit_i) + (CurrentCredit_t – TaxLiability_t)

Where the total credit available in year t is the sum of the current year’s generated credit and all unexpired carry forwards from the previous seven years (summed from i=t-7 to t-1). The TaxLiability_t refers to the CAT due after any preceding credits in the R.C. 5751.98 order have been applied.

The Strategic Importance of the 280C Election

While Ohio QREs generally follow federal QREs, the treatment of the federal 280C election is a common area of confusion. Under federal law, taxpayers can either take a full credit and reduce their deductible R&D expenses by the credit amount, or take a “reduced credit” under Section 280C. Because Ohio’s CAT is a gross receipts tax and does not allow for a deduction of research expenses anyway, the 280C election primarily impacts the federal income tax return. However, ODT auditors will often review the 280C election on Federal Form 6765 to verify the consistency of the QRE figures being reported to the state.

Interaction with JobsOhio and Other Programs

The R&D Investment Tax Credit does not exist in a vacuum; it is often part of a larger incentive package. R.C. 5751.51 can be paired with programs like the JobsOhio R&D Investment Loan. This program offers low-interest financing for R&D projects and can include a separate loan repayment CAT credit (R.C. 5751.52).

Strategic considerations for businesses include:

• Pairing Nonrefundable with Refundable Credits: A business might use the nonrefundable R&D credit to offset its entire CAT liability and then monetize a refundable Jobs Creation Credit to receive a check from the state.
• Sales Tax Exemption: Businesses conducting R&D in Ohio are also eligible for a sales and use tax exemption on machinery and equipment used primarily for research. This provides an immediate cash-flow benefit that complements the deferred benefit of the CAT credit carry forward.

Audit Red Flags and Common Pitfalls

The ODT’s “aggressive audit policy” centers on several recurring themes that can lead to the denial of carry forward credits:

• Jurisdictional Creep: Claiming wages for a software engineer who lives and works in Kentucky but reports to a Cincinnati office. ODT guidance is clear: the research must be performed in Ohio.
• Inadequate Time Tracking: Using “estimations” or “percentage allocations” for staff time rather than contemporaneous logs. ODT Final Determinations have repeatedly ruled against taxpayers who cannot provide granular proof of time spent on specific qualified projects.
• Base Amount Manipulation: “Forgetting” to include research expenses in the prior three years to artificially inflate the current year’s incremental credit. Auditors will look at 3-5 years of history to ensure the base is accurate.
• Failure to File CAT CS: Claiming a credit on the main CAT return without attaching the required Credit Schedule. This can result in an automatic denial and a request for documentation within sixty days.

Future Outlook and Legislative Trends

The future of the Ohio R&D tax credit is marked by a trend toward simplification for small businesses and increased scrutiny for large ones. The elimination of the AMT and the rise of the exclusion to $6,000,000 effectively “exempts” thousands of small innovators from the CAT regime. However, these companies must still track their R&D spending if they hope to utilize carry forwards once they scale.

For large-scale taxpayers, the focus is on “sound audit policy.” The 2023 amendments to R.C. 5751.51 regarding audit sampling suggest that the state intends to maintain a high bar for what constitutes “qualified” research. As other states (like California or Arizona) offer different carry forward durations or refundability options, Ohio’s competitive position remains tied to its relatively simple 7% rate and its clear, if strict, seven-year carry forward window.

Final Thoughts

The Ohio R&D tax credit and its carry forward mechanism provide a robust, if temporally limited, incentive for innovation. By understanding the interaction between R.C. 5751.51, the shifting CAT exclusion thresholds of 2024-2025, and the ODT’s rigorous documentation standards, businesses can effectively manage their tax liabilities. The carry forward serves as a critical safety valve, preserving the value of research investments during periods of low revenue or legislative change, and remains a vital component of Ohio’s business-friendly tax code. Success in claiming and retaining these credits depends on a thorough alignment with federal standards, a strict adherence to jurisdictional boundaries, and a “defense-ready” approach to record-keeping.